nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—CES2—Phase I biotransformations, non P450—PON1—amyotrophic lateral sclerosis	0.0626	0.214	CbGpPWpGaD
Dabigatran etexilate—Subarachnoid haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.0464	0.0919	CcSEcCtD
Dabigatran etexilate—CES1—Phase I biotransformations, non P450—PON1—amyotrophic lateral sclerosis	0.0369	0.126	CbGpPWpGaD
Dabigatran etexilate—F2—forelimb—amyotrophic lateral sclerosis	0.0343	0.169	CbGeAlD
Dabigatran etexilate—F2—hindlimb—amyotrophic lateral sclerosis	0.0308	0.152	CbGeAlD
Dabigatran etexilate—Haematocrit decreased—Riluzole—amyotrophic lateral sclerosis	0.0272	0.0538	CcSEcCtD
Dabigatran etexilate—F2—appendage—amyotrophic lateral sclerosis	0.0264	0.13	CbGeAlD
Dabigatran etexilate—CES2—E2F transcription factor network—UXT—amyotrophic lateral sclerosis	0.0239	0.0818	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of IGF Activity by IGFBP—IGFALS—amyotrophic lateral sclerosis	0.0235	0.0804	CbGpPWpGaD
Dabigatran etexilate—Cerebral haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.0183	0.0362	CcSEcCtD
Dabigatran etexilate—Haemoglobin decreased—Riluzole—amyotrophic lateral sclerosis	0.0147	0.0291	CcSEcCtD
Dabigatran etexilate—Thrombosis—Riluzole—amyotrophic lateral sclerosis	0.0143	0.0283	CcSEcCtD
Dabigatran etexilate—CES1—E2F transcription factor network—UXT—amyotrophic lateral sclerosis	0.0141	0.0482	CbGpPWpGaD
Dabigatran etexilate—NQO2—hindbrain—amyotrophic lateral sclerosis	0.014	0.0689	CbGeAlD
Dabigatran etexilate—Haemoptysis—Riluzole—amyotrophic lateral sclerosis	0.0137	0.0271	CcSEcCtD
Dabigatran etexilate—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.0112	0.0222	CcSEcCtD
Dabigatran etexilate—Gout—Riluzole—amyotrophic lateral sclerosis	0.0108	0.0215	CcSEcCtD
Dabigatran etexilate—Blood bilirubin increased—Riluzole—amyotrophic lateral sclerosis	0.0107	0.0212	CcSEcCtD
Dabigatran etexilate—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00915	0.0181	CcSEcCtD
Dabigatran etexilate—Hepatic function abnormal—Riluzole—amyotrophic lateral sclerosis	0.00841	0.0167	CcSEcCtD
Dabigatran etexilate—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.0081	0.0161	CcSEcCtD
Dabigatran etexilate—NQO2—brainstem—amyotrophic lateral sclerosis	0.00802	0.0395	CbGeAlD
Dabigatran etexilate—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00753	0.0149	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00735	0.0146	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.00735	0.0146	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00678	0.0134	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00662	0.0131	CcSEcCtD
Dabigatran etexilate—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.0065	0.0129	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00648	0.0128	CcSEcCtD
Dabigatran etexilate—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00635	0.0126	CcSEcCtD
Dabigatran etexilate—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00635	0.0126	CcSEcCtD
Dabigatran etexilate—CES2—medulla oblongata—amyotrophic lateral sclerosis	0.00626	0.0308	CbGeAlD
Dabigatran etexilate—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00619	0.0123	CcSEcCtD
Dabigatran etexilate—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00611	0.0121	CcSEcCtD
Dabigatran etexilate—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00609	0.0121	CcSEcCtD
Dabigatran etexilate—F2—Regulation of IGF Activity by IGFBP—IGFBP3—amyotrophic lateral sclerosis	0.00588	0.0201	CbGpPWpGaD
Dabigatran etexilate—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.0057	0.0113	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00566	0.0112	CcSEcCtD
Dabigatran etexilate—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00566	0.0112	CcSEcCtD
Dabigatran etexilate—NQO2—medulla oblongata—amyotrophic lateral sclerosis	0.00559	0.0275	CbGeAlD
Dabigatran etexilate—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00558	0.0111	CcSEcCtD
Dabigatran etexilate—CES2—spinal cord—amyotrophic lateral sclerosis	0.00558	0.0275	CbGeAlD
Dabigatran etexilate—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00555	0.011	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.0055	0.0109	CcSEcCtD
Dabigatran etexilate—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.0054	0.0107	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00536	0.0106	CcSEcCtD
Dabigatran etexilate—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00534	0.0106	CcSEcCtD
Dabigatran etexilate—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00531	0.0105	CcSEcCtD
Dabigatran etexilate—CES2—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.00526	0.018	CbGpPWpGaD
Dabigatran etexilate—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00511	0.0101	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00508	0.0101	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00502	0.00995	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00501	0.00992	CcSEcCtD
Dabigatran etexilate—F2—spinal cord—amyotrophic lateral sclerosis	0.005	0.0246	CbGeAlD
Dabigatran etexilate—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.005	0.0099	CcSEcCtD
Dabigatran etexilate—NQO2—spinal cord—amyotrophic lateral sclerosis	0.00498	0.0245	CbGeAlD
Dabigatran etexilate—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00498	0.00987	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00472	0.00935	CcSEcCtD
Dabigatran etexilate—CES2—nervous system—amyotrophic lateral sclerosis	0.0047	0.0231	CbGeAlD
Dabigatran etexilate—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00461	0.00914	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00459	0.0091	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00458	0.00908	CcSEcCtD
Dabigatran etexilate—CES2—central nervous system—amyotrophic lateral sclerosis	0.00452	0.0223	CbGeAlD
Dabigatran etexilate—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00443	0.00877	CcSEcCtD
Dabigatran etexilate—CES2—cerebellum—amyotrophic lateral sclerosis	0.00442	0.0218	CbGeAlD
Dabigatran etexilate—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00436	0.00864	CcSEcCtD
Dabigatran etexilate—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00428	0.00848	CcSEcCtD
Dabigatran etexilate—F2—nervous system—amyotrophic lateral sclerosis	0.00422	0.0208	CbGeAlD
Dabigatran etexilate—NQO2—nervous system—amyotrophic lateral sclerosis	0.0042	0.0207	CbGeAlD
Dabigatran etexilate—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00409	0.00811	CcSEcCtD
Dabigatran etexilate—F2—central nervous system—amyotrophic lateral sclerosis	0.00406	0.02	CbGeAlD
Dabigatran etexilate—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00404	0.00801	CcSEcCtD
Dabigatran etexilate—NQO2—central nervous system—amyotrophic lateral sclerosis	0.00404	0.0199	CbGeAlD
Dabigatran etexilate—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00397	0.00786	CcSEcCtD
Dabigatran etexilate—NQO2—cerebellum—amyotrophic lateral sclerosis	0.00395	0.0195	CbGeAlD
Dabigatran etexilate—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00391	0.00775	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00389	0.00771	CcSEcCtD
Dabigatran etexilate—CES1—nervous system—amyotrophic lateral sclerosis	0.00387	0.0191	CbGeAlD
Dabigatran etexilate—Cough—Riluzole—amyotrophic lateral sclerosis	0.00386	0.00765	CcSEcCtD
Dabigatran etexilate—CES2—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.00385	0.0132	CbGpPWpGaD
Dabigatran etexilate—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00382	0.00757	CcSEcCtD
Dabigatran etexilate—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00377	0.00747	CcSEcCtD
Dabigatran etexilate—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00377	0.00747	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00374	0.00741	CcSEcCtD
Dabigatran etexilate—CES1—central nervous system—amyotrophic lateral sclerosis	0.00373	0.0183	CbGeAlD
Dabigatran etexilate—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00361	0.00716	CcSEcCtD
Dabigatran etexilate—CES2—brain—amyotrophic lateral sclerosis	0.00359	0.0177	CbGeAlD
Dabigatran etexilate—Infection—Riluzole—amyotrophic lateral sclerosis	0.00359	0.00711	CcSEcCtD
Dabigatran etexilate—Shock—Riluzole—amyotrophic lateral sclerosis	0.00355	0.00704	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00354	0.00702	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00354	0.00701	CcSEcCtD
Dabigatran etexilate—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00351	0.00695	CcSEcCtD
Dabigatran etexilate—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00337	0.00669	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00329	0.00652	CcSEcCtD
Dabigatran etexilate—F2—Complement and Coagulation Cascades—C5AR1—amyotrophic lateral sclerosis	0.00324	0.0111	CbGpPWpGaD
Dabigatran etexilate—F2—brain—amyotrophic lateral sclerosis	0.00322	0.0159	CbGeAlD
Dabigatran etexilate—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00322	0.00638	CcSEcCtD
Dabigatran etexilate—NQO2—brain—amyotrophic lateral sclerosis	0.00321	0.0158	CbGeAlD
Dabigatran etexilate—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00318	0.0063	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00312	0.00618	CcSEcCtD
Dabigatran etexilate—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00311	0.00617	CcSEcCtD
Dabigatran etexilate—CES1—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.0031	0.0106	CbGpPWpGaD
Dabigatran etexilate—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00309	0.00612	CcSEcCtD
Dabigatran etexilate—CES2—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.00297	0.0102	CbGpPWpGaD
Dabigatran etexilate—CES1—brain—amyotrophic lateral sclerosis	0.00296	0.0146	CbGeAlD
Dabigatran etexilate—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00295	0.00585	CcSEcCtD
Dabigatran etexilate—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00287	0.00569	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—GSR—amyotrophic lateral sclerosis	0.00286	0.0098	CbGpPWpGaD
Dabigatran etexilate—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00285	0.00566	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00266	0.00527	CcSEcCtD
Dabigatran etexilate—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00259	0.00513	CcSEcCtD
Dabigatran etexilate—UGT2B15—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	0.00259	0.00886	CbGpPWpGaD
Dabigatran etexilate—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00256	0.00506	CcSEcCtD
Dabigatran etexilate—F2—Regulation of IGF Activity by IGFBP—IGF1—amyotrophic lateral sclerosis	0.00248	0.0085	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00247	0.0049	CcSEcCtD
Dabigatran etexilate—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00239	0.00473	CcSEcCtD
Dabigatran etexilate—CES2—Fluoropyrimidine Activity—TP53—amyotrophic lateral sclerosis	0.00235	0.00805	CbGpPWpGaD
Dabigatran etexilate—CES2—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.00232	0.00795	CbGpPWpGaD
Dabigatran etexilate—F2—Post-translational protein modification—PIGW—amyotrophic lateral sclerosis	0.00232	0.00793	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.0023	0.00455	CcSEcCtD
Dabigatran etexilate—Rash—Riluzole—amyotrophic lateral sclerosis	0.00228	0.00451	CcSEcCtD
Dabigatran etexilate—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00228	0.00451	CcSEcCtD
Dabigatran etexilate—CES1—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.00227	0.00777	CbGpPWpGaD
Dabigatran etexilate—Headache—Riluzole—amyotrophic lateral sclerosis	0.00226	0.00448	CcSEcCtD
Dabigatran etexilate—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.00221	0.00757	CbGpPWpGaD
Dabigatran etexilate—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00215	0.00425	CcSEcCtD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—SOD1—amyotrophic lateral sclerosis	0.002	0.00685	CbGpPWpGaD
Dabigatran etexilate—ABCB1—embryo—amyotrophic lateral sclerosis	0.00189	0.0093	CbGeAlD
Dabigatran etexilate—UGT2B7—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.00178	0.00609	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—PFN1—amyotrophic lateral sclerosis	0.00176	0.00601	CbGpPWpGaD
Dabigatran etexilate—CES1—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.00175	0.00599	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—SOD1—amyotrophic lateral sclerosis	0.00163	0.00558	CbGpPWpGaD
Dabigatran etexilate—F2—IL1 and megakaryotyces in obesity—MMP9—amyotrophic lateral sclerosis	0.00162	0.00556	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.00154	0.00527	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.00151	0.00518	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—APOE—amyotrophic lateral sclerosis	0.00148	0.00506	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—IGFALS—amyotrophic lateral sclerosis	0.00145	0.00496	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.00145	0.00495	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—TUBA4A—amyotrophic lateral sclerosis	0.00142	0.00487	CbGpPWpGaD
Dabigatran etexilate—F2—Complement and Coagulation Cascades—C3—amyotrophic lateral sclerosis	0.00141	0.00484	CbGpPWpGaD
Dabigatran etexilate—CES1—Fluoropyrimidine Activity—TP53—amyotrophic lateral sclerosis	0.00139	0.00475	CbGpPWpGaD
Dabigatran etexilate—CES1—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.00137	0.00468	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.0013	0.00446	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—SOD1—amyotrophic lateral sclerosis	0.00129	0.00443	CbGpPWpGaD
Dabigatran etexilate—F2—Syndecan-4-mediated signaling events—MMP9—amyotrophic lateral sclerosis	0.00129	0.00441	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—PFN1—amyotrophic lateral sclerosis	0.00128	0.00439	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—C5AR1—amyotrophic lateral sclerosis	0.00127	0.00435	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.00125	0.00428	CbGpPWpGaD
Dabigatran etexilate—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.00121	0.00594	CbGeAlD
Dabigatran etexilate—UGT2B7—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	0.00118	0.00403	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00116	0.00397	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00116	0.00397	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—PIGW—amyotrophic lateral sclerosis	0.0011	0.00376	CbGpPWpGaD
Dabigatran etexilate—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.00108	0.0053	CbGeAlD
Dabigatran etexilate—UGT2B15—Metabolism—VAPA—amyotrophic lateral sclerosis	0.00106	0.00363	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.00106	0.00363	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.00106	0.00362	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—XRN2—amyotrophic lateral sclerosis	0.00101	0.00344	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.00101	0.00344	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000986	0.00338	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000964	0.0033	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	0.000958	0.00328	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000927	0.00317	CbGpPWpGaD
Dabigatran etexilate—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000907	0.00446	CbGeAlD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000882	0.00302	CbGpPWpGaD
Dabigatran etexilate—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000873	0.0043	CbGeAlD
Dabigatran etexilate—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000853	0.0042	CbGeAlD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000852	0.00292	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—DAO—amyotrophic lateral sclerosis	0.000839	0.00287	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—YIF1A—amyotrophic lateral sclerosis	0.000833	0.00285	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.00082	0.00281	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000817	0.00279	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000786	0.00269	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000771	0.00264	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.000734	0.00251	CbGpPWpGaD
Dabigatran etexilate—ABCB1—brain—amyotrophic lateral sclerosis	0.000693	0.00341	CbGeAlD
Dabigatran etexilate—UGT2B7—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.00069	0.00236	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—EXOSC9—amyotrophic lateral sclerosis	0.000686	0.00235	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.000683	0.00234	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.000682	0.00234	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.00068	0.00233	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.000661	0.00226	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	0.000655	0.00224	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000649	0.00222	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000639	0.00219	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000636	0.00218	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	0.00062	0.00212	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—GSR—amyotrophic lateral sclerosis	0.000587	0.00201	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—TUBA4A—amyotrophic lateral sclerosis	0.000577	0.00198	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.00056	0.00192	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.000556	0.0019	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—PLA2G4A—amyotrophic lateral sclerosis	0.000556	0.0019	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—C3—amyotrophic lateral sclerosis	0.000555	0.0019	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000553	0.00189	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CASP9—amyotrophic lateral sclerosis	0.000547	0.00187	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000528	0.00181	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000528	0.00181	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000528	0.00181	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—DCTN1—amyotrophic lateral sclerosis	0.000491	0.00168	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—TP53—amyotrophic lateral sclerosis	0.000491	0.00168	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000483	0.00165	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000482	0.00165	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000449	0.00154	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CD40LG—amyotrophic lateral sclerosis	0.00044	0.00151	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000429	0.00147	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000429	0.00147	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000422	0.00145	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.0004	0.00137	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000393	0.00134	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—C3—amyotrophic lateral sclerosis	0.000389	0.00133	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000383	0.00131	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—DAO—amyotrophic lateral sclerosis	0.000382	0.00131	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	0.000378	0.00129	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000372	0.00127	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000371	0.00127	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000367	0.00125	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000365	0.00125	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—IGFBP3—amyotrophic lateral sclerosis	0.000363	0.00124	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000349	0.0012	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000343	0.00117	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000333	0.00114	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—SOD1—amyotrophic lateral sclerosis	0.00032	0.00109	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000319	0.00109	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—DAO—amyotrophic lateral sclerosis	0.00031	0.00106	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PLB1—amyotrophic lateral sclerosis	0.00029	0.000991	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	0.000287	0.000981	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000283	0.000969	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.00027	0.000924	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSR—amyotrophic lateral sclerosis	0.000267	0.000914	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.00026	0.000888	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000259	0.000886	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	0.000247	0.000845	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000244	0.000835	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000238	0.000814	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000235	0.000805	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000231	0.000792	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	0.00023	0.000788	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000228	0.000779	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	0.000226	0.000772	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000224	0.000767	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000219	0.000751	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000217	0.000743	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSR—amyotrophic lateral sclerosis	0.000217	0.000743	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000205	0.000703	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000199	0.000681	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.000198	0.000677	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000197	0.000674	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000197	0.000674	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000197	0.000673	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—APOE—amyotrophic lateral sclerosis	0.000196	0.00067	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	0.000195	0.000669	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—IGF1—amyotrophic lateral sclerosis	0.000195	0.000667	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	0.00018	0.000616	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000178	0.00061	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000175	0.000598	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000175	0.000598	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000167	0.000573	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000164	0.000563	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	0.000163	0.000557	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.00016	0.000548	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000157	0.000539	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000156	0.000533	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—IGF1—amyotrophic lateral sclerosis	0.000153	0.000524	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	0.000148	0.000505	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000145	0.000497	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	0.000142	0.000487	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000135	0.000462	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PTGS2—amyotrophic lateral sclerosis	0.000134	0.000459	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—VEGFA—amyotrophic lateral sclerosis	0.000127	0.000435	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000127	0.000434	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	0.000122	0.000419	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000121	0.000413	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000118	0.000404	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000114	0.000389	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	0.000111	0.000381	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000108	0.000371	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000108	0.000369	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000103	0.000354	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	9.96e-05	0.000341	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	9.72e-05	0.000332	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	9.65e-05	0.00033	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TP53—amyotrophic lateral sclerosis	9.62e-05	0.000329	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.58e-05	0.000328	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—APOE—amyotrophic lateral sclerosis	8.92e-05	0.000305	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.81e-05	0.000301	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—C3—amyotrophic lateral sclerosis	8.59e-05	0.000294	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	8.18e-05	0.00028	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	7.99e-05	0.000274	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	7.29e-05	0.000249	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—APOE—amyotrophic lateral sclerosis	7.25e-05	0.000248	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	6.61e-05	0.000226	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.11e-05	0.000209	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.08e-05	0.000174	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.96e-05	0.00017	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.81e-05	0.000164	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.4e-05	0.00015	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.31e-05	0.000148	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.04e-05	0.000138	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	3.32e-05	0.000114	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.26e-05	0.000112	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.28e-05	7.79e-05	CbGpPWpGaD
